Dr Lal Pathlabs
Neuberg, NM Medical consolidate Maharashtra operations, eye wider reach
The combined Maharashtra business is expected to generate around ₹500 crore in revenue this year, with plans to establish a presence in every district headquarters
 "Neuberg, NM Medical consolidate Maharashtra operations, eye wider reach")
IDBI Bank, Lal PathLabs, Welspun Living: Top stock ideas by Choice Broking
Stocks to buy today: IDBI Bank has moved above both its 50-day EMA, which indicates that the near-term trend is turning positive, says Sachin Gupta of Choice Broking.
 "IDBI Bank, Lal PathLabs, Welspun Living: Top stock ideas by Choice Broking")
Dr Lal PathLabs expands advanced diagnostics portfolio with genomics buy
The ₹168 crore acquisition of a 70 per cent stake in SN Genelab is expected to strengthen Dr Lal's genomics expertise and broaden its advanced diagnostics portfolio
 "Dr Lal PathLabs expands advanced diagnostics portfolio with genomics buy")
Robust demand, stable pricing to keep diagnostics volumes strong in FY27
Brokerages expect diagnostic majors to sustain volume growth through FY27, aided by robust demand and stable pricing, though the recent stock rally may cap upside
 "Robust demand, stable pricing to keep diagnostics volumes strong in FY27")
Robust demand, pricing to keep volumes strong for diagnostics sector
Brokerages expect listed diagnostics majors to maintain volume growth through FY27, helped by stable pricing, B2C demand and operating leverage
 "Robust demand, pricing to keep volumes strong for diagnostics sector")
Robust demand, pricing to keep volumes strong for diagnostics sector
Brokerages expect listed diagnostics majors to maintain volume growth through FY27, helped by stable pricing, B2C demand and operating leverage
DCB Bank, Dr Lal Path among Kotak Securities' top tech ideas; here's why
Geographically, DCB has a diversified pan-India presence with a stronger footprint across western and southern India, while continuing to expand selectively into underpenetrated markets.
 "DCB Bank, Dr Lal Path among Kotak Securities' top tech ideas; here's why")
Dr Lal Path jumps 8% to 52-week high on Q1 beat; up to 25% upside on cards
Dr Lal PathLabs' share price jumped 8 per cent to a fresh 52-week high of ₹1,893.65 on the BSE today. The company has posted a better-than-expected Q1 show, prompting analysts to raise target prices.
 "Dr Lal Path jumps 8% to 52-week high on Q1 beat; up to 25% upside on cards")
Dr Lal PathLabs jumps 5% after Q1 PAT surges 21%; ₹5 dividend declared
Dr Lal PathLabs' consolidated net profit grew by 21.4 per cent Y-o-Y to ₹170 crore in Q1 of FY27.
 "Dr Lal PathLabs jumps 5% after Q1 PAT surges 21%; ₹5 dividend declared")
Dr Lal PathLabs soars 11%, hits 52-week high on huge volumes; here's why
Care Ratings expects Dr Lal PathLabs' revenue to grow by 11-12 per cent per annum in the near-to-medium term driven by organic demand growth, its expanding geographical presence and new initiatives.
 "Dr Lal PathLabs soars 11%, hits 52-week high on huge volumes; here's why")
Healthcare stocks shine in weak market; Metropolis, Thyrocare jump upto 14%
Metropolis Healthcare share hit a 52-week high of ₹574.45, surging 14 per cent in trade. Thyrocare soared 12 per cent to ₹526.10, while Vijaya Diagnostic Centre gained 7 per cent to ₹1,298.45.
 "Healthcare stocks shine in weak market; Metropolis, Thyrocare jump upto 14%")
Dr Lal PathLabs hits 20% upper band on strong Q4; brokerages stay positive
Dr. Lal PathLabs recorded a 16.6 per cent Y-o-Y rise in revenue from operations to ₹702 crore in Q4 FY26 from ₹659.8 crore in the year-ago period
 "Dr Lal PathLabs hits 20% upper band on strong Q4; brokerages stay positive")
Dr Lal PathLabs Q4FY26 results: Net profit falls 15%; revenue rises 16.6%
Diagnostics firm reports profit decline due to prior-year tax benefit, while revenue growth remains strong on higher sample volumes and improved test mix
Dr Lal Path Labs Q4 FY26 results: Profit down 15.5%, revenue up 16.6%
Consolidated net profit fell to 1.31 billion rupees ($13.8 million) in the quarter ended March, from 1.55 billion rupees a year earlier
Dr Lal back on the acquisition trail, tests South India for opportunities
After a three-year strategic pause, diagnostics firm is unlocking its balance-sheet capacity look for growth-boosting acquisitions
 "Dr Lal back on the acquisition trail, tests South India for opportunities")
Dr Lal back on the acquisition trail, tests South India for opportunities
After a three-year strategic pause, diagnostics firm is unlocking its balance-sheet capacity look for growth-boosting acquisitions
Dr Lal PathLabs Q3 net profit falls 6.4% on new labour code impact
Diagnostics major reports a one-time charge linked to new labour codes even as revenue rose over 10% on higher sample volumes and network expansion
Dr Lal Path Labs Q3 results: PAT dips to ₹90.5 cr on labour code changes
The country's largest diagnostics firm by revenue took up a one-time charge worth ₹30.1 crore linked to India's new labour codes
Dr Lal Path Labs Q3 results: PAT dips to ₹90.5 cr on labour code changes
The country's largest diagnostics firm by revenue took up a one-time charge worth ₹30.1 crore linked to India's new labour codes
HDFC Sec turns bullish on Dr Lal PathLabs; upgrades to 'Buy'; raises target
Dr Lal PathLabs is focusing on innovation, including new wellness packages and high-end, super-speciality tests, with a focus on capturing prescription shares